Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

ACI-19764

Source date not recordedAnalyse record ↗

Brain-penetrant NLRP3 inhibitor in a recruiting Phase 1/1b study of inflammatory target engagement.

Modality
oral brain-penetrant small-molecule NLRP3 inflammasome inhibitor
Availability (US)
Phase 1/1b study Recruiting
Biomarkers
adverse events; pharmacokinetics; pharmacodynamics; high-sensitivity C-reactive protein; inflammatory markers
Hallmark targeted
chronic inflammation, altered intercellular communication, neuroinflammation
Kind
investigational drug
Clinical trials
NCT07463196 — Phase 1, Recruiting on September 2, 2026 update